Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

The FDA reviews odronextamab's application for relapsed lymphoma, highlighting trial enrollment issues but confirming safety and efficacy.

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus ...

Pfizer CEO Albert Bourla said his company is in “very active discussions” over Trump’s request concerning most-favoured-nation pricing, according to news website FiercePharma. Bourla said he had ...

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday after market hours. Here’s ...

AstraZeneca, which last week announced a $50bn plan for US development, declined to comment. Pfizer, Abbvie, and Germany’s ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

The FDA issued another complete response letter for odronextamab for the treatment of relapsed/refractory follicular lymphoma.

In patients with diabetic macular edema in both eyes, the port delivery system in one eye achieves a superior anatomical ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.